Inquiry Basket
Loading ......
Vancomycin has been a cornerstone of therapy against serious Gram-positive bacterial infections for more than half a century, valued especially for activity against methicillin-resistant Staphylococcus aureus and against enterococci when few alternatives remain. Its usefulness rests on a deceptively simple interaction with the bacterial cell wall, and for decades that interaction was thought to be nearly impossible for bacteria to evade. Experience has shown otherwise. Resistance to vancomycin has emerged, moved through hospitals, and in some regions become endemic, turning a dependable drug into a contested one.
Vancomycin works by binding to the terminal D-alanyl-D-alanine moiety of the peptidoglycan precursor lipid II, the building block that bacteria add to a growing cell wall. This binding blocks the cross-linking reactions that give the wall its strength, so the cell swells and breaks under its own internal pressure. Resistance does not alter vancomycin itself; instead, it remodels the target the drug is supposed to grip. Rather than presenting D-alanyl-D-alanine at the precursor tip, a resistant cell substitutes D-alanyl-D-lactate, or in some systems D-alanyl-D-serine. That single chemical change removes one of the hydrogen bonds vancomycin depends on and introduces steric and electrostatic repulsion, dropping the antibiotic's affinity for its target by roughly a thousandfold. The result is that cell wall assembly proceeds essentially unhindered even in the presence of the drug. Understanding resistance therefore begins with understanding this substitution, because it is the shared foundation beneath every vancomycin-resistant phenotype.
Figure 1. Mode of action of vancomycin. (Source: Healy VL, et al. 2000)
Enterococci are the principal reservoir in which vancomycin resistance first took hold and from which it spreads. These organisms have acquired clusters of van genes that reprogram the cell wall assembly line. The best-studied clusters are organized around a two-component regulatory system, VanR and VanS, in which the membrane-bound sensor detects vancomycin and switches on the rest of the program. Downstream enzymes then carry out the remodeling: one enzyme reduces pyruvate to D-lactate, a ligase joins D-alanine to that D-lactate to form the resistant dipeptide, and a dipeptidase trims away any remaining native D-alanyl-D-alanine so that only the low-affinity precursor is used. Additional proteins fine-tune the phenotype, including one that modestly raises resistance to related glycopeptides. Expression is typically inducible, ramping up only when the drug is near. The VanA type confers high-level resistance to both vancomycin and teicoplanin, whereas the VanB type is resistant to vancomycin with variable susceptibility to teicoplanin. Research has shown that these gene clusters are often carried on a transposon, frequently lodged on conjugative plasmids, which is precisely what makes them so mobile between cells.
The most alarming leap is the transfer of a complete van operon from a vancomycin-resistant enterococcus into Staphylococcus aureus, producing true vancomycin-resistant S. aureus. This is rare, but each documented case is treated as a sentinel event because it joins two serious resistances - methicillin resistance and vancomycin resistance - in one organism. The circumstances that enable it usually involve a patient simultaneously carrying both a resistant enterococcus and MRSA, with close contact between the two species and an environment, such as a biofilm, that favors conjugation. A more common and insidious route to reduced vancomycin susceptibility in S. aureus is stepwise chromosomal change. Under prolonged or repeated vancomycin exposure, strains accumulate multiple mutations that thicken the cell wall and trap the drug in outer layers, so progressively less reaches its target. Isolates with intermediate susceptibility mark this continuum, and within a single population some cells may already tolerate higher drug levels than the rest. That gradient between fully susceptible and frankly resistant is where much of the clinical difficulty now lives.
Figure 2. Schematic model illustrating the acquisition and molecular mechanism of vanA-type vancomycin resistance in S. aureus. (Source: McGuinness WA, et al. 2017)
Heteroresistance describes a population that looks susceptible as a whole yet harbors a small subpopulation able to grow at vancomycin concentrations far above the reported minimum inhibitory concentration. Standard susceptibility testing reports the dominant population and can miss the resistant minority, so a clinician may reasonably conclude the isolate is treatable when part of it is not. The danger is practical: when vancomycin is given, the susceptible majority is suppressed while the hidden subpopulation survives, persists, and can expand, producing treatment failure, prolonged bacteremia, and relapse. A recent prospective cohort of adults with MRSA bloodstream infection found heteroresistance in roughly one in five cases and linked it to prior vancomycin exposure; strikingly, among patients whose strains were heteroresistant, those treated with vancomycin had markedly worse outcomes than those whose strains were fully susceptible. These findings argue that heteroresistance is not a laboratory curiosity but a clinically meaningful state, possibly a precursor to frank resistance, and that specialized tests able to expose resistant subpopulations deserve a larger role in routine care.
Detection rests on a hierarchy of methods, each answering a different question. Phenotypic susceptibility testing establishes whether an isolate falls into the susceptible, intermediate, or resistant category and quantifies the minimum inhibitory concentration. Because colonized patients silently drive transmission, active screening of at-risk individuals with samples from the lower gastrointestinal tract is a mainstay of infection control; growth on selective medium is followed by confirmation so that carriers can be isolated and contact precautions applied. Molecular approaches detect the van genes directly, often more rapidly and with information valuable for control measures, while confirmation of high-level resistance in S. aureus specifically requires demonstrating the acquired operon by molecular means. Heteroresistance demands still more demanding quantitative profiling that resolves subpopulations rather than a single value. Every one of these steps depends on reagents of known performance: defined growth media, validated controls, and nucleic-acid assays calibrated against reference materials. Research-grade recombinant proteins, specific antibodies, and standardized panels are what allow a screening result or a molecular call to mean the same thing from one laboratory to the next, which is the quiet prerequisite for any trustworthy surveillance program.
The prevalence of vancomycin-resistant enterococci varies dramatically by region and even between neighboring countries, shaped by antibiotic use, the intensity of infection-control practice, and patient mix. One cross-border scoping review found hospital prevalence climbing above twenty percent in some settings while remaining below one percent in others, with a shift over time from one resistance type to another as clones rose and fell. Elsewhere, multi-year hospital surveillance has recorded detection rising sharply within a few years of first isolation, often through the spread of a few dominant clones rather than a single outbreak. These patterns matter because they are not inevitable; they respond to stewardship that curbs unnecessary glycopeptide use and to contact precautions that interrupt patient-to-patient spread. Surveillance is therefore not merely counting, but the feedback loop that tells a hospital whether its controls are working. Where that loop is weak, resistant strains quietly establish themselves and become the baseline, at which point the therapeutic options narrow for exactly the patients who already have the fewest.
References
| Target | Cat. No. | Product Name | Species | Application | Detection Sample | ||
| Vancomycin | DEIANJ11 | Human Vancomycin ELISA Kit | 96T | Human | Quantitative and Qualitative | Human serum, plasma | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Vancomycin | DMABT-54924MV | Anti-Vancomycin monoclonal antibody, clone WBO2 | Mouse | IgM | IA | Inquiry |
| HMABPY054 | RHA™ anti-Vancomycin monoclonal antibody, clone VM | Mouse | IgG | ELISA, LFIA | Inquiry | |
| DMABT-Z60038 | Anti-Vancomycin monoclonal antibody, clone 4H22 | Mouse | IgM | ELISA, ICC/IF | Inquiry | |
| CABT-LH054 | Mouse Anti-Vancomycin monoclonal antibody, clone 30 | Mouse | IgG | ELISA, LFIA | Inquiry | |
| DPBT-68293SV | Anti- Vancomycin polyclonal antibody | Sheep | IgG | ELISA | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| Vancomycin | DAG3035 | Vancomycin [BSA] | N/A | BSA | N/A | Inquiry |
| DAG3036 | Vancomycin [HRP] | N/A | HRP | N/A | Inquiry | |
| DAG3035O | Vancomycin [OVA] | N/A | OVA | N/A | Inquiry | |
| DAG152S | Vancomycin [HSA] | N/A | HSA | ELISA | Inquiry | |
| DAG465S | Vancomycin [HSA-Biotin] | N/A | HSA-Biotin | ELISA | Inquiry | |
| DAG-WT2710 | Vancomycin control | N/A | Unconjugated | Calibration, Control | Inquiry | |
| DAGA-053K | Vancomycin [KLH] | N/A | KLH | Immunogen | Inquiry |
Loading ......
